Lumvoa (veligrotug-vvze) Continuation Therapy
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and continuation of Lumvoa (veligrotug-vvze) for members with thyroid eye disease under the MassHealth UPPL. It applies to medical-benefit coverage and notes that Lumvoa is also available through the pharmacy benefit.
Lumvoa injection was added to both the pharmacy and medical benefits with a prior authorization requirement.
The policy added a glucocorticoid step-through requirement and requires confirmation of no historical treatment with Tepezza.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.